As I'm sure many of you have heard, they have started phase I's for vaccines against SARS-CoV-2:
- NCT04283461 Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection (US National Institute of Allergy and Infectious Diseases)
- NCT04299724 Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine (Shenzhen Geno-Immune Medical Institute)
- NCT04276896 Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus (Shenzhen Geno-Immune Medical Institute)
Specifically focusing on the US NIAID vaccine, it is an RNA-based vaccine. From what I understand, RNA based vaccines have had a lot of problems in the past with efficacy. There was a good review on mRNA vaccines published in Nature Reviews Drug Discovery (open access PMCID: PMC5906799). Though it appears like this is a large topic of active research, the authors of this paper made it seem as if mRNA based vaccines were not yet scaleable on to the population level (the review was written in 2018). Is anyone aware of any specific features of this current mRNA-1273 vaccine that might improve its efficacy? In general, how hopeful are you that it will make it past phase II and III?
Also…. I wanted to discuss this apparent misunderstanding by the lay-public. Whenever I see posts or articles about this vaccine it seems like people think this will be the one and that it will out very soon. I worry that people do not understand how long the phases take. Have any of you noticed anything similar?
Lastly, I am unfamiliar with the mechanism of the two other vaccines being tested by the Shenzhen group. If anyone knows more about them it would be great to hear about their strengths/weaknesses, or really anything at all.
Source: Original link